NeuroScientific Biopharmaceuticals Limited (ASX:NSB)

ASX:NSB Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	-	2.21	4.95	-	0.96
Revenue	-	2.21	4.95	-	0.96
Revenue Growth (YoY)	-	-55.34%	-	-	-
Cost of Revenue	-0	0.02	0.05	0.07	0.04
Gross Profit	0	2.19	4.91	-0.07	0.92
Selling, General & Admin	0.99	1.36	1.75	1.8	1.28
Research & Development	0.13	0.49	4.03	7.22	2.22
Amortization of Goodwill & Intangibles	0.09	0.09	0.05	0.05	0.05
Operating Expenses	2.01	2.03	6.08	10.44	4.18
Operating Income	-2.01	0.16	-1.17	-10.5	-3.26
Interest Expense	-0	-0.01	-0	-	-0
Interest & Investment Income	0.17	0.18	0.11	0.07	0.03
Other Non Operating Income (Expenses)	-	-	-	-	0
EBT Excluding Unusual Items	-1.85	0.32	-1.07	-10.44	-3.24
Other Unusual Items	-	-	-	-	0.06
Pretax Income	-1.85	0.32	-1.07	-10.44	-3.18
Net Income	-1.85	0.32	-1.07	-10.44	-3.18
Net Income to Common	-1.85	0.32	-1.07	-10.44	-3.18
Shares Outstanding (Basic)	147	145	143	143	143
Shares Outstanding (Diluted)	147	145	143	143	143
Shares Change (YoY)	1.49%	0.72%	-	-	83.04%
EPS (Basic)	-0.01	0.00	-0.01	-0.07	-0.02
EPS (Diluted)	-0.01	0.00	-0.01	-0.07	-0.02
Free Cash Flow	-0.94	0.04	-2.3	-6.95	-2.63
Free Cash Flow Per Share	-0.01	-	-0.02	-0.05	-0.02
Gross Margin	-	98.90%	99.07%	-	95.87%
Operating Margin	-	7.02%	-23.65%	-	-340.53%
Profit Margin	-	14.66%	-21.57%	-	-331.45%
Free Cash Flow Margin	-	1.92%	-46.52%	-	-274.46%
EBITDA	-1.92	0.25	-1.11	-10.44	-3.2
EBITDA Margin	-	11.15%	-22.48%	-	-
D&A For EBITDA	0.09	0.09	0.06	0.06	0.06
EBIT	-2.01	0.16	-1.17	-10.5	-3.26
EBIT Margin	-	7.02%	-23.65%	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.